Abstract
Most trials have one site (or more) which excels at recruitment and adds patients at a greater rate than others. In a reasonable attempt to complete recruitment into a trial these sites are often encouraged to continue adding patients despite generating a disproportionate number of patients. This study uses the TOPKAT data to demonstrate the potential danger of this frequent practice. TOPKAT is a multi-centre NIHR HTA sponsored surgical trial of over 500 patients designed to compare the cost efficacy of partial versus total knee replacement in the NHS using the Oxford Knee Score as primary variable. One year follow up results are now available on 531 patients. A single centre recruited 107 out of a total of 531 patients. Despite successful randomisation and balance between groups the baseline demographics and self-reported data was different in this single centre compared to that for the entire study sample. Furthermore, the differences found in the primary outcome for the main study at 1 year were not reflected in the sub analysis of the single site. Had the conclusions been based on the data from the single site, an entirely different interpretation for the study results would have been appropriate. The difference in the conclusion obtained from the two different data sets cannot be dismissed because of the high proportion of patients (20%) from the single centre. The work highlights the perils of allowing a single centre to over recruit.
Highlights
Most trials have one site which excels at recruitment and adds patients at a greater rate than others
This study uses the TOPKAT data to demonstrate the potential danger of this frequent practice
Despite successful randomisation and balance between groups the baseline demographics and self-reported data was different in this single centre compared to that for the entire study sample
Summary
Most trials have one site (or more) which excels at recruitment and adds patients at a greater rate than others. Is over recruitment to a single site problematic for surgical trials? David Beard*, Andrew Price, David Murray, Loretta Davies, Cushla Cooper, Jonathan Cook, TOPKAT STUDY GROUP From 3rd International Clinical Trials Methodology Conference Glasgow, UK.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.